Skip to content

Ronnie Shapira‐Frommer

Sheba Medical Center

1 paper in the Anchorcite directory, published in 2015, cited 6,034 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations

    BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…

Metadata from OpenAlex (CC0).